Sichuan Hebang Biotechnology Co LtdMethionine segment profits boosted by supply gap and price rise due to raw material shortages from geopolitical conflicts.

Hebang Biotech disclosed an earnings forecast, expecting net profit attributable to shareholders of the listed company for the first half of 2026 to be between 370 million and 430 million yuan, an increase of 614.68% to 730.57% year-on-year. In the first half, affected by geopolitical conflicts, the methionine industry saw overall production capacity decline due to raw material shortages, widening the supply gap and raising the cost base, which drove a rapid increase in methionine prices and boosted segment profits. Also affected by geopolitical conflicts, the cost of raw materials such as yellow phosphorus rose rapidly, and the United States included elemental phosphorus and key herbicides like glyphosate in its list of critical strategic materials, pushing up prices of glyphosate and diglyphosate and significantly improving segment profits.
Sichuan Hebang Biotechnology Co LtdMethionine segment profits boosted by supply gap and price rise due to raw material shortages from geopolitical conflicts.